KdT Ventures

KdT Ventures is an early-stage venture capital firm that invests in startups in the data, engineering, and biology sector, as well as healthcare technology systems, pharmaceuticals, biotechnology, agriculture, chemicals, gases, and life sciences. The firm was founded in 2017 in Austin, Texas by Cain McClary.

Rima Chakrabarti

Partner

Cain McClary

Founder and Managing Partner

Ketan Yerneni

Principal

53 past transactions

Equii

Seed Round in 2022
Equii is a food technology company that discovers highly nutritious sources of microbial proteins that are used to ferment grains and produce high-protein grain flours. Founded in 2021 by Monica Bhatia, Equii is based in San Ramon, California.

Tavros Therapeutics

Seed Round in 2022
Tavros Therapeutics is an emerging biotechnology company that discovers and develops therapies for cancer. The company was founded in 2019 and based in Durham, North Carolina.

Canaery

Seed Round in 2022
Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Unravel Biosciences

Seed Round in 2022
Unravel Biosciences is a therapeutics company spun out from the Wyss Institute at Harvard University that develops new therapeutics for complex disorders by using existing drugs to discover and clinically validate new targets. By integrating a proprietary large action model of human health with rapid in vivo screening and clinical validation of discovered targets, our AI-powered discovery engine uncovers new drug targets for complex disorders and leveraging existing drugs to clinically derisk the discovered novel biology 2-3x faster and >10x cheaper than competing approaches. Unravel’s platform has been validated with discoveries that are being translated to 4 clinical trials, and the company has established a wide range of partnerships through its rareSHIFT™ services arm that has resulted in rapid therapeutics pipeline, IP portfolio, and clinical sample expansion while being net profitable.

Zeta Surgical

Seed Round in 2022
Zeta Surgical is a digital surgery company focused on improving the accuracy, safety, and accessibility of image guided procedures. Its navigation and robotics platform, Zeta, leverages cutting-edge computer vision and artificial intelligence to enable image guidance directly at the point-of-care, creating new possibilities in fields such as emergency care and interventional medicine. Zeta Surgical was founded by Harvard graduates and faculty and is partnered with leading hospitals and universities.

Terray Therapeutics

Series A in 2022
Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the company addresses complex therapeutic challenges across various targets.

Marigold Health

Seed Round in 2022
Marigold Health uses AI-augmented chat support groups to reach and retain patients with behavioral health needs in community-based treatment. Patients receive a personalized wraparound support while care teams see dramatic gains in capacity using patients to engage each other. We partner directly with treatment providers and managed care organizations in the Medicaid market.

Faeth Therapeutics

Seed Round in 2022
Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.

Greeneye Technology

Series A in 2021
Greeneye utilizes Artificial Intelligence to disrupt the agricultural pest control process, transitioning from the current practice of broadcast and wasteful spraying to precise and selective spraying of herbicides. Greeneye developed a proprietary selective spraying (SPP) system that turns every sprayer into a smart machine with seamless integration, Greeneye’s SSP system can detect weeds and spray them precisely in real-time, reducing up to 90% of herbicide usage. Demo - https://www.youtube.com/watch?v=iCOuTemX_cc&feature=youtu.be Greeneye is a leading technology company with a focus in precision agriculture, established in 2017 and based in Tel-Aviv, Israel. Greeneye has a multidisciplinary team with expertise in computer vision, artificial intelligence, agronomy, mechanical engineering, spraying applications, etc. We work with an extraordinary group of talented and visionary people who are committed to provide sustainable solutions for farmers around the world.

Zymochem

Seed Round in 2021
Zymochem provides a carbon-efficient bio-manufacturing platform that converts renewable feedstocks into bio-based materials without compromising price, performance, scale, or sustainability while minimizing CO2 loss during production. It also accelerates a real-zero economy by relieving carbon emissions in product development, use, and end-of-life.

Parthenon Therapeutics

Series A in 2021
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

54gene

Series B in 2021
54gene is a healthcare startup unlocking the African genome to fuel genetic research and development that may lead to new discoveries and benefit all populations. 54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market: Nearly 90% of genetic material used in pharmaceutical research is caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.

Debut

Series A in 2021
Debut is an unconventional innovation company that integrates breakthrough biotechnology and brand creation to build businesses that represent the next generation of sustainable wellness. With proprietary screening, testing, and cell-free biomanufacturing technology, we unlock novel activities to power global personal care and health brands. Their mission is to set a new standard for big business through a dynamic intrapreneurial model and to create purposeful brands that push humanity forward. The company creates sustainable novel ingredients, products, and brands that will accelerate the transformation of the industry.

Andes

Series A in 2021
Andes develops an integrated microbial technology to help accelerate crop growth. Its technology is combined with artificial intelligence to develop its seeds while reducing input costs and environmental footprints and helps farmers to boost their agricultural output and income. Andes was founded in 2018 and is headquartered in Alameda, California.

Modulus Therapeutics

Seed Round in 2021
Modulus Therapeutics is an artificial-intelligence-powered cell therapy design company.

Xilis

Series A in 2021
Xilis is a biotechnology company that develops technologies to guide precision therapy for cancer patients and accelerate drug discovery. The company's platform enables diagnostics, drug screening, and scalable patient-derived models for drug discovery, enabling physicians and pharmaceutical companies to develop tailored treatments for patients by conducting drug screening.

PathAI

Series C in 2021
PathAI’s services solve challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making accurate diagnoses for every patient, every time. The company was founded in 2016 and is based in Boston, Massachusetts.

Dyno Therapeutics

Series A in 2021
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

Rejuvenate Bio

Series A in 2021
Rejuvenate Bio is a biotechnology company that develops therapies to reverse aging and treat age-related diseases. Founded on research from the Wyss Institute at Harvard Medical School, Rejuvenate Bio has developed innovative therapies aimed at addressing chronic age-related diseases in both humans and animals. The company has established a gene therapy pipeline with significant potential in treating chronic diseases. They leverage clinically validated gene targets and an effective delivery method to ensure long-lasting and well-tolerated gene expression.

SeQure Dx

Venture Round in 2021
SeQure Dx provides safety data for on and off-target CRISPR gene editing therapies

Theator

Series A in 2021
Theator is a surgical intelligence platform that combines artificial intelligence and computer vision to improve surgeon performance. Its platform is powered by Visual AI that puts defining intraoperative moments in the hands of surgeons so they can continuously perfect their craft. Theator is partnering with visionary surgeons and hospitals to help create a more transparent OR while empowering surgeons to raise their expertise to the highest possible level.

Onc.AI

Venture Round in 2020
Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics. The company develops a comprehensive approach to oncology diagnostics and uses deep learning to derive actionable insights into oncology treatment. It was founded in 2020 by Akshay Nanduri and Salmaan Ahmed and is based in San Carlos, California, United States.

Dimension Inx

Venture Round in 2020
Dimension Inx specializes in developing regenerative microenvironments that give the body a blueprint to heal itself. Its biomaterials platform embraces the complex interplay between material composition, microstructure, and microarchitecture to produce biofunctionality within the body. The company was founded in 2017 and is headquartered in Chicago, Illinois.

Andes

Seed Round in 2020
Andes develops an integrated microbial technology to help accelerate crop growth. Its technology is combined with artificial intelligence to develop its seeds while reducing input costs and environmental footprints and helps farmers to boost their agricultural output and income. Andes was founded in 2018 and is headquartered in Alameda, California.

Abridge

Series A in 2020
Abridge is a healthcare technology company that uses generative AI to automate the transcription and summarization of medical discussions. The platform transforms patient-clinician conversations into structured clinical notes in real-time, integrating with Electronic Health Record (EHR) systems. It reduces the need for manual note-taking, enhances patient understanding by generating clear, understandable summaries, and ensures that documentation is added to patient records. Abridge prioritizes data security and patient privacy, complying with healthcare regulations while offering a customizable interface tailored to patient needs.

Rarebird

Seed Round in 2020
Rarebird is a coffee company featuring Arabica coffee beans that deliver improved mental wellness outcomes. It partners with 3rd party coffee sources to ensure that its beans are procured ethically and sustainably, bringing value to producers and consumers alike.

Andes

Seed Round in 2020
Andes develops an integrated microbial technology to help accelerate crop growth. Its technology is combined with artificial intelligence to develop its seeds while reducing input costs and environmental footprints and helps farmers to boost their agricultural output and income. Andes was founded in 2018 and is headquartered in Alameda, California.

Xilis

Seed Round in 2020
Xilis is a biotechnology company that develops technologies to guide precision therapy for cancer patients and accelerate drug discovery. The company's platform enables diagnostics, drug screening, and scalable patient-derived models for drug discovery, enabling physicians and pharmaceutical companies to develop tailored treatments for patients by conducting drug screening.

54gene

Series A in 2020
54gene is a healthcare startup unlocking the African genome to fuel genetic research and development that may lead to new discoveries and benefit all populations. 54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market: Nearly 90% of genetic material used in pharmaceutical research is caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.

Circularis Biotechnologies

Seed Round in 2020
Circularis Biotechnologies develops a revolutionary technology to regulate gene expression and enable increased biotherapeutic production. It was founded in 2014 and is headquartered in Oakland, California.

Solugen

Series B in 2020
Solugen is a venture-backed biotech company that replaces petroleum-based products with plant-derived substitutes. They combine the elements of fermentation with the elements of petrochemical processing to create the carbon negative molecular manufacturing platform. They produces chemicals from bio-based feedstocks and is based on breakthroughs in synthetic biology, metal catalyst engineering, and modular plant design. Its solutions will also address clean water, sustainable materials, safer food, and healthy personal care.

Character Biosciences

Seed Round in 2020
Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Circularis Biotechnologies

Seed Round in 2020
Circularis Biotechnologies develops a revolutionary technology to regulate gene expression and enable increased biotherapeutic production. It was founded in 2014 and is headquartered in Oakland, California.

Debut

Seed Round in 2020
Debut is an unconventional innovation company that integrates breakthrough biotechnology and brand creation to build businesses that represent the next generation of sustainable wellness. With proprietary screening, testing, and cell-free biomanufacturing technology, we unlock novel activities to power global personal care and health brands. Their mission is to set a new standard for big business through a dynamic intrapreneurial model and to create purposeful brands that push humanity forward. The company creates sustainable novel ingredients, products, and brands that will accelerate the transformation of the industry.

Azitra

Series A in 2019
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

54gene

Seed Round in 2019
54gene is a healthcare startup unlocking the African genome to fuel genetic research and development that may lead to new discoveries and benefit all populations. 54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market: Nearly 90% of genetic material used in pharmaceutical research is caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.

Solugen

Series B in 2019
Solugen is a venture-backed biotech company that replaces petroleum-based products with plant-derived substitutes. They combine the elements of fermentation with the elements of petrochemical processing to create the carbon negative molecular manufacturing platform. They produces chemicals from bio-based feedstocks and is based on breakthroughs in synthetic biology, metal catalyst engineering, and modular plant design. Its solutions will also address clean water, sustainable materials, safer food, and healthy personal care.

Theator

Seed Round in 2019
Theator is a surgical intelligence platform that combines artificial intelligence and computer vision to improve surgeon performance. Its platform is powered by Visual AI that puts defining intraoperative moments in the hands of surgeons so they can continuously perfect their craft. Theator is partnering with visionary surgeons and hospitals to help create a more transparent OR while empowering surgeons to raise their expertise to the highest possible level.

Checkerspot

Series A in 2019
Checkerspot is a materials innovation company that designs materials at a molecular level. The company is driven by a mission to use the power of biotechnology to expand the palette of molecular building blocks for high-performance and sustainable materials.

Terray Therapeutics

Seed Round in 2019
Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the company addresses complex therapeutic challenges across various targets.

Hi Fidelity Genetics

Series A in 2018
Hi Fidelity Genetics is a start up based in Durham, NC. They develop tools to measure and predict plant traits. Such tools are essential for maintaining a sufficient supply of food as the world's population grows and its climate changes.

Abridge

Seed Round in 2018
Abridge is a healthcare technology company that uses generative AI to automate the transcription and summarization of medical discussions. The platform transforms patient-clinician conversations into structured clinical notes in real-time, integrating with Electronic Health Record (EHR) systems. It reduces the need for manual note-taking, enhances patient understanding by generating clear, understandable summaries, and ensures that documentation is added to patient records. Abridge prioritizes data security and patient privacy, complying with healthcare regulations while offering a customizable interface tailored to patient needs.

Dyno Therapeutics

Seed Round in 2018
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

Visla Labs

Seed Round in 2018
Visla Labs is a startup that is constructing the sci-fi future of healthcare. They have venture capital backing and are rapidly approaching an inflection point.

Tierra Biosciences

Seed Round in 2018
Tierra Biosciences is an operator of a synthetic biology company intended to accelerate the pace of discovery to enable the next generation of bioengineered products. The company's protein platform leverages cell-free protein production and artificial intelligence and couples high-throughput protein manufacturing with the simplicity of e-commerce.

Checkerspot

Seed Round in 2018
Checkerspot is a materials innovation company that designs materials at a molecular level. The company is driven by a mission to use the power of biotechnology to expand the palette of molecular building blocks for high-performance and sustainable materials.

Sepsis Scout

Seed Round in 2018
Artificial Intelligence and Wearables to detect sepsis in the at home care setting.

Azitra

Convertible Note in 2018
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Elemental Machines

Series A in 2018
Elemental Machines is revolutionizing science-based industries with a smart lab platform that offers powerful, data-driven insights to improve laboratory operations, research, development, and manufacturing outcomes. Continuously monitoring equipment and environmental variables provides new levels of clarity, transparency, consistency, and improved repeatability and gathers new data sets for advanced analytics.

Elemental Machines

Series A in 2018
Elemental Machines is revolutionizing science-based industries with a smart lab platform that offers powerful, data-driven insights to improve laboratory operations, research, development, and manufacturing outcomes. Continuously monitoring equipment and environmental variables provides new levels of clarity, transparency, consistency, and improved repeatability and gathers new data sets for advanced analytics.

Hi Fidelity Genetics

Series A in 2017
Hi Fidelity Genetics is a start up based in Durham, NC. They develop tools to measure and predict plant traits. Such tools are essential for maintaining a sufficient supply of food as the world's population grows and its climate changes.

PathAI

Series A in 2017
PathAI’s services solve challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making accurate diagnoses for every patient, every time. The company was founded in 2016 and is based in Boston, Massachusetts.

Solugen

Seed Round in 2017
Solugen is a venture-backed biotech company that replaces petroleum-based products with plant-derived substitutes. They combine the elements of fermentation with the elements of petrochemical processing to create the carbon negative molecular manufacturing platform. They produces chemicals from bio-based feedstocks and is based on breakthroughs in synthetic biology, metal catalyst engineering, and modular plant design. Its solutions will also address clean water, sustainable materials, safer food, and healthy personal care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.